Compare SHOP & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOP | NVO |
|---|---|---|
| Founded | 2004 | 1923 |
| Country | Canada | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.7B | 199.4B |
| IPO Year | 2014 | 2001 |
| Metric | SHOP | NVO |
|---|---|---|
| Price | $145.91 | $46.28 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 33 | 11 |
| Target Price | ★ $164.44 | $51.00 |
| AVG Volume (30 Days) | 6.9M | ★ 9.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.19% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $11,556,000,000.00 | N/A |
| Revenue This Year | $29.34 | N/A |
| Revenue Next Year | $23.77 | $3.70 |
| P/E Ratio | $204.80 | ★ $13.60 |
| Revenue Growth | ★ 30.14 | N/A |
| 52 Week Low | $94.00 | $35.12 |
| 52 Week High | $182.19 | $64.16 |
| Indicator | SHOP | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 52.05 |
| Support Level | $144.12 | $43.25 |
| Resistance Level | $171.94 | $48.23 |
| Average True Range (ATR) | 4.64 | 0.98 |
| MACD | -2.02 | 0.07 |
| Stochastic Oscillator | 33.09 | 63.82 |
Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.